Telesis Bio (Telesis Bio) Change In Receivables : $-1.33 Mil (TTM As of Dec. 2023)

View and export this data going back to 2021. Start your Free Trial

What is Telesis Bio Change In Receivables?

Telesis Bio's change in receivables for the quarter that ended in Dec. 2023 was $-1.83 Mil. It means Telesis Bio's Accounts Receivable increased by $1.83 Mil from Sep. 2023 to Dec. 2023 .

Telesis Bio's change in receivables for the fiscal year that ended in Dec. 2023 was $-1.33 Mil. It means Telesis Bio's Accounts Receivable increased by $1.33 Mil from Dec. 2022 to Dec. 2023 .

Telesis Bio's Accounts Receivable for the quarter that ended in Dec. 2023 was $5.99 Mil.

Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed. Telesis Bio's Days Sales Outstanding for the three months ended in Dec. 2023 was 78.28.

In Ben Graham's calculation of liquidation value, Apple Inc's Accounts Receivable are only considered to be worth 75% of book value. Telesis Bio's liquidation value for the three months ended in Dec. 2023 was $-15.21 Mil.

Telesis Bio Change In Receivables Historical Data

The historical data trend for Telesis Bio's Change In Receivables can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Telesis Bio Change In Receivables Chart

Telesis Bio Annual Data

Trend

Dec19

Dec20

Dec21

Dec22

Dec23

Change In Receivables

-0.77

-0.74

-2.53

-1.33

Telesis Bio Quarterly Data
	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Change In Receivables	Get a 7-Day Free Trial												-0.53	0.02	-2.41	2.88	-1.83

Telesis Bio Change In Receivables Calculation

Change In Accounts Receivable relative to the previous period. It is any increase or decrease in the cash a company is owed by its customers.

Change In Receivables for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-1.33 Mil.

Telesis Bio (NAS:TBIO) Change In Receivables Explanation

1. Accounts Receivable are created when a customer has received a product but has not yet paid for that product. Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.

Telesis Bio's Days Sales Outstanding for the quarter that ended in Dec. 2023 is calculated as:

	Days Sales Outstanding
=	Accounts Receivable	/	Revenue	*	Days in Period
=	5.985	/	6.977	*	91
=	78.28

2. In Ben Graham's calculation of liquidation value, Telesis Bio's accounts receivable are only considered to be worth 75% of book value:

Telesis Bio's liquidation value for the quarter that ended in Dec. 2023 is calculated as:

	Liquidation Value
=	Cash, Cash Equivalents, Marketable Securities	-	Total Liabilities	+	(0.75 * Accounts Receivable)	+	(0.5 * Total Inventories)
=	19.158	-	40.873	+	0.75 * 5.985	+	0.5 * 4.025
=	-15.21

Telesis Bio Change In Receivables Related Terms

Thank you for viewing the detailed overview of Telesis Bio's Change In Receivables provided by GuruFocus.com. Please click on the following links to see related term pages.

Telesis Bio (Telesis Bio) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Telesis Bio Inc (NAS:TBIO) » Definitions » Change In Receivables

Comparable Companies

Traded in Other Exchanges

N/A

Address

10431 Wateridge Circle, Suite 150, San Diego, CA, USA, 92121

Website

https://www.telesisbio.com

Telesis Bio Inc is a synthetic biology company focused on enabling researchers to rapidly, accurately, and reproducibly build or write high-quality synthetic DNA and mRNA that is ready to use in many downstream synthetic biology-enabled markets. It manufactures and sells laboratory equipment, specifically synthetic biology instruments, reagents, and associated products and related services. Its products comprise of BioXp system, BioXp kits, Benchtop reagents, Coronavirus tools, and BioXp biofoundry services.

Executives

Gregory J. Herrema	director	355 RIVER OAKS PARKWAY, SAN JOSE CA 95134
Marijn E Dekkers	10 percent owner	GENERAL ELECTRIC COMPANY, 41 FARNSWORTH STREET, BOSTON MA 02210
Novalis Lifesciences Investments Ii Gp, Llc	10 percent owner	1 LIBERTY LANE E, SUITE 112, HAMPTON NH 03842
Novalis Lifesciences Investments Ii, L.p.	10 percent owner	1 LIBERTY LANE E, SUITE 112, HAMPTON NH 03842
Broadoak Fund Iv, Llc	10 percent owner	4800 MONTGOMERY LANE, SUITE 230, BETHESDA MD 20814
William Snider	director, 10 percent owner	4800 MONTGOMERY LANE, SUITE 230, BETHESDA MD 20814
Paul M Meister	director, 10 percent owner	18 SHIP ROCK ROAD, NORTH HAMPTON NH 03862
Rob Cutler	officer: Chief Legal Officer	C/O TELESIS BIO, INC., 9535 WAPLES STREET, SUITE 100, SAN DIEGO CA 92121
Daniel Glenn Gibson	officer: Chief Technology Officer	C/O CODEX DNA, INC., 9535 WAPLES STREET, SUITE 100, SAN DIEGO CA 92121
Todd Robert Nelson	director, 10 percent owner, officer: President & CEO	C/O CODEX DNA, INC., 9535 WAPLES STREET, SUITE 100, SAN DIEGO CA 92121
Eric Eugene Esser	officer: Chief Operating Officer	C/O CODEX DNA, INC., 9535 WAPLES STREET, SUITE 100, SAN DIEGO CA 92121
Annette Tumolo	director	C/O BIO-RAD LABORATORIES, INC., 1000 ALFRED NOBEL DRIVE, HERCULES CA 94547
Northpond Ventures Gp, Llc	10 percent owner	7500 OLD GEORGETOWN ROAD, SUITE 850, BETHESDA MD 20814
Northpond Ventures Gp Ii, Llc	10 percent owner	7500 OLD GEORGETOWN ROAD, SUITE 850, BESTHESDA MD 20814
Northpond Ventures Ii, Lp	10 percent owner	7500 OLD GEORGETOWN ROAD, SUITE 850, BETHESDA MD 20814